Is there room for a new way to drug RNA? ARCH, Foresite join Atlas, The Column Group for $81M bet
By now, it appears that drug hunters have exploited just about every therapeutic angle having to do with RNA. Leveraging RNA as a therapy? Check. Making antisense oligonucleotides that induce a particular change? Check. Finding small molecules that bind to RNA, targeting the enzymes that modify it, or even creating a way to edit it letter by letter? Check, check, check. But Atlas and The Column Group — both active investors of those efforts — saw yet another approach to be tried.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.